Figure 3From: Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands Cost-effectiveness (Euro/QALY and Euro/LY) for the bivalent and quadrivalent HPV vaccine. Black: Euros per life year gained; red: Euros per quality-adjusted life years gained; circles: quadrivalent vaccine; squares: bivalent vaccine.Back to article page